This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Timothy Weeden
Sr. Director - Head of Platform Development at Dyne Therapeutics

Profile

Tim Weeden is a leading researcher in the field of oligonucleotide therapeutics, with over 20 years of experience in discovery and development of small molecules, peptides, and antibody therapeutics across areas of immunology and rare disease. Tim joined Dyne Therapeutics at its inception and played a leading role in the design of the company’s FORCE™ platform. He currently serves as Senior Director and Head of Platform Development. Prior to Dyne, Tim spent 15 years at Genzyme, a Sanofi Company, where he held multiple roles with increasing responsibility focused on therapeutic discovery research for immune mediated diseases, oncology, neuroimmunology, and rare-diseases. He started his career at New England Peptide where he focused on custom peptide synthesis and polyclonal antibody generation. Tim has authored a number of patents and peer-reviewed articles published in leading scientific journals, including Molecular-Therapy, Peptide Science, Neuroimmunology, and Nucleic acid Therapeutics. Tim holds a B.S. degree in Biochemistry from Bridgewater State University.  

Agenda Sessions

  • FORCE(TM) Platform for Targeted Delivery of Oligonucleotide Therapeutics in Muscle Diseases

    11:15am

Speakers at this event